natgillin/translations-raw huggingface dataset:
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vylaer Spiromax, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The Committee recommended that Vylaer Spiromax be given marketing authorisation. 
Priporočil je, da se za zdravilo Vylaer Spiromax izda dovoljenje za promet.
What are the benefits and risks of Vylaer Spiromax? 
Kakšne so koristi in tveganja, povezani z zdravilom Vylaer Spiromax?
When inhaled it mainly attaches to the receptors in the airways and causes the muscles to relax, which keeps the airways open and helps with the patient's breathing. 
Ob vdihu se v glavnem veže na receptorje v dihalnih poteh in sprošča mišice, s čimer ohranja dihalne poti odprte in bolniku olajša dihanje.
Vylaer Spiromax is a medicine that contains the active substances budesonide and formoterol. 
Vylaer Spiromax je zdravilo, ki vsebuje zdravilni učinkovini budezonid in formoterol.
Other information about Vylaer Spiromax 
Druge informacije o zdravilu Vylaer Spiromax
Vylaer Spiromax is a ‘hybrid medicine'. 
Zdravilo Vylaer Spiromax je „hibridno zdravilo“.
Why is Vylaer Spiromax approved? 
Zakaj je bilo zdravilo Vylaer Spiromax odobreno?
How does Vylaer Spiromax work? 
Kako zdravilo Vylaer Spiromax deluje?
How is Vylaer Spiromax used? 
Kako se zdravilo Vylaer Spiromax uporablja?
It is not intended to provide practical advice on how to use Vylaer Spiromax. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Date of first authorisation: 8 December 2014 Date of latest renewal: 23 September 2019 
Datum prve odobritve: 8. december 2014 Datum zadnjega podaljšanja: 23. september 2019
Patients over 65 years of age have been represented in the phase III studies. 
Bolniki, starejši od 65 let, so bili zastopani v študijah III. faze.
Not known (frequency cannot be estimated from the available data): 
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov):
Northumberland, NE61 3YA United Kingdom 
Northumberland, NE61 3YA Velika Britanija
• if your opioid medicine is to be stopped for more than 24 hours 
• če morate svoje opioidno zdravilo nehati jemati za več kot 24 ur.
• Stir and drink immediately 
• Zmešajte in takoj popijte.
• excessive sweating 
• prekomerno znojenje
Of the 844 patients who were randomized, 61.1% completed the study (defined as completing the 2-week follow-up visit after the 52-week treatment period). 
Od 844 randomiziranih bolnikov jih je študijo dokončalo 61,1 % (dokončanje je bilo opredeljeno kot opravljen 2-tedenski spremljevalni pregled po 52-tedenskem obdobju zdravljenja).
Constipation related to opioids can result in symptoms such as: 
Zaprtje, povezano z opioidi, lahko povzroči simptome, kakršni so:
Opioid withdrawal symptoms may affect up to 1 in 100 people. 
Simptomi odtegnitve opioidov se lahko pojavijo pri največ 1 od 100 bolnikov.
Food effects: A high-fat meal increased the extent and rate of naloxegol absorption. 
Vplivi hrane: Zelo masten obrok je povečal obseg in hitrost absorpcije naloksegola.
Tablets are engraved with “nGL” on one side and the strength of the tablet on the other. 
Tablete imajo vtisnjeno oznako »nGL« na eni strani in jakost tablete na drugi strani.
What Moventig is and what it is used for 
Kaj je zdravilo Moventig in za kaj ga uporabljamo
Tell your doctor what opioid pain medicines you are taking and the dose of them. 
Zdravniku povejte, katera opioidna zdravila proti bolečinam jemljete in v kakšnem odmerku.
Do not take Moventig if you are taking any of the following medicines (see section “Do not take Moventig”): 
Ne jemljite zdravila Moventig, če jemljete katero od naslednjih zdravil (glejte poglavje »Ne jemljite zdravila Moventig«):
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli za oznako »EXP«.
The observed neoplastic changes are well known hormonal and centrally mediated effects in the rat which are not relevant for humans. 
Opažene neoplastične spremembe so dobro znani hormonski in centralno posredovani učinki pri podganah, ki za človeka niso pomembni.
According to the ICH E14 Guideline, this is considered a definitively negative thorough QT/QTc study. 
Po smernici ICH E14 ta študija velja za jasno negativno temeljito študijo QT/QTc.
• if you have had a heart attack within the last 6 months, have heart failure with daily shortness of breath or other severe problems with your heart which cause daily symptoms 
• če ste imeli srčni infarkt v zadnjih 6 mesecih, imate srčno popuščanje z vsakodnevnim težkim dihanjem ali imate druge težave s srcem, ki vam povzročajo vsakodnevne simptome,
Moventig is not recommended for use in children and adolescents below 18 years of age because it has not been studied in these age-groups. 
Zdravila Moventig pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljivo uporabljati, ker v teh starostnih skupinah ni raziskano.
Most such reports were observed shortly after initial administration with the medicinal product and were mild or moderate in intensity. 
Večino takšnih primerov so opažali kmalu po začetni uporabi zdravila in so bili blagi ali zmerni.
(≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
(≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost
• if you experience symptoms of opioid withdrawal syndrome (see section 4 below). 
• če se vam pojavijo simptomi sindroma odtegnitve opioidov (glejte poglavje 4 spodaj).
At therapeutic doses, most opioids (e.g. morphine, meperidine, methadone) are excreted into breast milk in minimal amounts. 
V terapevtskih odmerkih se večina opioidov (npr. morfin, meperidin, metadon) izloča v materino mleko v minimalni količini.
What Moventig is and what it is used for What you need to know before you take Moventig How to take Moventig 
Kaj je zdravilo Moventig in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Moventig Kako jemati zdravilo Moventig
Your doctor may tell you to take a lower dose of 12.5 mg 
Zdravnik vam bo morda naročil, da jemljite manjši odmerek 12,5 mg:
• Crush the tablet to a powder 
• Zdrobite tableto v prašek.
This could be a symptom of damage to the wall of the gut and can be life-threatening. 
To je lahko simptom poškodbe stene črevesa, ki je lahko smrtno nevarna.
The mean apparent volume of distribution during the terminal phase (Vz/F) in healthy volunteers ranged from 968 to 2,140 L across dosing groups and studies. 
Povprečni navidezni volumen porazdelitve med terminalno fazo (Vz/F) je bil pri zdravih prostovoljcih od 968 do 2.140 l v skupinah z različnim odmerjanjem in v različnih študijah.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or any other opioid antagonist. 
Preobčutljivost Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1, ali na kateri koli drug opioidni antagonist.
Long-term safety and tolerability 
Dolgoročna varnost in prenašanje
A QTc study performed with naloxegol in healthy volunteers did not indicate any prolongation of the QT interval. 
Študija intervala QTc, ki so jo izvedli z naloksegolom pri zdravih prostovoljcih, ni pokazala podaljšanja intervala QT.
All these effects were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. 
Vse te učinke so opazili samo pri izpostavljenosti, ki je močno presegala največjo izpostavljenost pri človeku, kar kaže na majhen pomen za klinično uporabo.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Pharmacotherapeutic group: Drugs for constipation, peripheral opioid receptor antagonists ATC code: A06AH03 
Farmakoterapevtska skupina: zdravila proti zaprtju, periferno delujoči antagonisti opioidnih receptorjev; oznaka ATC: A06AH03
In clinical pharmacology studies, the half-life of naloxegol at therapeutic dose ranged from 6-11 hours. 
V kliničnih farmakoloških študijah je bil razpolovni čas naloksegola v terapevtskih odmerkih od 6 do 11 ur.
If you have trouble swallowing the tablet you can crush it and mix with water as follows: 
Če težko pogoltnete tableto Če težko pogoltnete tableto, jo lahko zdrobite in zmešate z vodo na naslednji način:
In a mass balance study in humans, a total of 6 metabolites were identified in plasma, urine and faeces. 
V študiji masnega ravnovesja pri človeku so v plazmi, urinu in blatu ugotovili skupaj 6 presnovkov.
• Do not take a double dose to make up for a missed dose. 
• Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
• hard stools (stools which are hard “like a rock”) 
• trdo blato (blato, ki je trdo »kot kamen«),
The primary objective was to assess long-term safety and tolerability for naloxegol 25 mg and to compare with usual care treatment using descriptive statistics. 
Primarni cilj je bila ocena dolgoročne varnosti in prenašanja 25 mg naloksegola in primerjava z običajnim zdravljenjem z uporabo opisnih statistik.
The overall benefit-risk profile for each patient should be taken into account. 
Upoštevati je treba celotno razmerje med koristjo in tveganjem pri vsakem bolniku.
Moventig has no or negligible influence on the ability to drive and use machines. 
Zdravilo Moventig nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Frequency categories are defined according to the following conventions: very common (≥ 1/10), common 
Kategorije pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni
As there are additional data from the use of this medicine in pregnant women, the use of Moventig during pregnancy is not recommended. 
Ker so na voljo dodatni podatki o uporabi tega zdravila pri nosečnicah, zdravila Moventig ni priporočljivo uporabljati med nosečnostjo.
The European Medicines Agency has deferred the obligation to submit the results of studies with Moventig in one or more subsets of the paediatric population in opioid induced constipation (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Moventig za eno ali več podskupin pediatrične populacije pri zaprtju, povzročenem z opioidi (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Moventig with drink 
Zdravilo Moventig skupaj s pijačo
• if you have kidney problems - your doctor may tell you to take a different dose (see section below “How to take Moventig”) 
• če imate težave z ledvicami - vaš zdravnik vam bo morda naročil, da jemljete drugačen odmerek (glejte poglavje spodaj »Kako jemati zdravilo Moventig«),
12 hours until your next dose, skip the missed dose. 
Če pa je do naslednjega odmerka manj kot 12 ur, pozabljeni odmerek izpustite.
Other medicines and Moventig 
Druga zdravila in zdravilo Moventig
What you need to know before you take Moventig Do not take Moventig: 
Kaj morate vedeti, preden boste vzeli zdravilo Moventig Ne jemljite zdravila Moventig:
• clarithromycin or telithromycin - antibiotics 
• klaritromicin ali telitromicin - antibiotika,
Following oral administration, naloxegol is absorbed rapidly, with peak concentrations (Cmax) achieved at less than 2 hours. 
Po peroralni uporabi se naloksegol hitro absorbira in največjo koncentracijo (Cmax) doseže v manj kot 2 urah.
Overall 393 and 317 patients had at least 6 and 12 months exposure to naloxegol 25 mg, respectively, in this study, which met the specified exposure requirements. 
V celoti je bilo v tej študiji 25 mg naloksegola vsaj 6 mesecev izpostavljenih 393 bolnikov in 12 mesecev 317 bolnikov, ki so izpolnili opredeljene zahteve o izpostavljenosti.
• methadone 
• metadon,
In some patients, however, a constellation of symptoms has been reported, which resembles the syndrome of central opioid withdrawal. 
Vendar je bil pri nekaterih bolnikih opisan skupek simptomov, ki spominja na sindrom centralne odtegnitve opioidov.
They were often reported as having a component of cramping discomfort. 
Pogosto je bilo poročano, da jih spremlja občutek nelagodja s krči.
Contents of the pack and other information What Moventig contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Moventig
Parent naloxegol excreted in the urine accounted for less than 6% of the total administered dose. 
V urinu izločeni matični naloksegol je predstavljal manj kot 6 % celotnega uporabljenega odmerka.
There is a small effect of age on the pharmacokinetics of naloxegol (approximately 0.7% increase in AUC for every year increase in age). 
Starost v majhni meri vpliva na farmakokinetiko naloksegola (približno 0,7 % zvišanje AUC za vsako dodatno leto starosti).
Opioid withdrawal syndrome typically develops within minutes to several days following administration of an opioid antagonist. 
Sindrom odtegnitve opioidov se značilno pojavi v nekaj minutah do nekaj dneh po dajanju antagonista opioidov.
A “symptom responder” was defined as meeting both the 12-week responder criteria and demonstrating improvement in pre-specified OIC symptoms and no deterioration in symptoms. 
Opazovani dogodek odziva simptomov »Odziv simptomov« je bil opredeljen kot izpolnitev 12-tedenskih meril odziva in hkrati dokazano izboljšanje vnaprej opredeljenih simptomov OIC, brez poslabšanja simptomov.
The primary objective was to compare safety and tolerability among the three treatment groups for an additional 12 weeks (beyond that observed in Kodiac 4) using descriptive statistics. 
Primarni cilj je bila primerjava varnosti in prenašanja v treh terapevtskih skupinah med obdobjem dodatnih 12 tednov (poleg obdobja v Kodiac 4) z uporabo opisnih statistik.
Safety and efficacy have not been established in patients with severe hepatic impairment (see section 5.2). 
Varnost in učinkovitost pri bolnikih s hudo okvaro jeter nista ugotovljeni (glejte poglavje 5.2).
The first of three multiplicity protected secondary endpoints was the 12-week responder rate in the LIR subgroup. 
Prvi od treh za večkratnost zavarovanih sekundarnih opazovanih dogodkov je bil 12-tedenski delež odzivnih bolnikov v podskupini LIR.
The safety and efficacy of naloxegol in children <18 years of age has not yet been established. 
Pediatrična populacija Varnost in učinkovitost naloksegola pri otrocih, mlajših od 18 let, še nista ugotovljeni.
However, in 2 out of 8 patients (in both the moderate and severe renal impairment groups but not in the end stage renal failure group) up to 10-fold increases in the exposure of naloxegol were observed. 
Toda pri 2 od 8 bolnikov (v skupini z zmerno in v skupini s hudo okvaro ledvic, ne pa v skupini s končno odpovedjo ledvic) so opazili do 10-krat večjo izpostavljenost naloksegolu.
• incomplete emptying of the rectum (after having a bowel movement, the feeling as if a stool is still in the rectum which needs to come out) 
• nepopolna izpraznitev danke (po iztrebljanju blata ostaja občutek, kot da je blato še vedno v danki in mora ven).
• Pour the powder into half a glass of water (120 ml) 
• Vsujte prašek v pol kozarca vode (120 ml).
Naloxegol was found to have no effect on fertility of male and female rats at oral doses up to 1,000 mg/kg per day (greater than 1,000 times the human therapeutic exposure (AUC) at the recommended human dose of 25 mg/day). 
Ugotovljeno je, da naloksegol ne vpliva na plodnost podganjih samcev in samic pri peroralnih odmerkih do 1.000 mg/kg na dan (več kot 1.000-kratna terapevtska izpostavljenost pri človeku (AUC) ob priporočenem odmerku za človeka
In all treatment groups, including placebo, improvements in PAC-SYM domains observed in Kodiac 4 were maintained for patients continuing in Kodiac 7. 
V vseh terapevtskih skupinah, tudi tisti s placebom, so se bolnikom, ki so nadaljevali v Kodiac 7, ohranila izboljšanja v domenah PAC-SYM, opažena v Kodiac 4.
Use in patients with severe hepatic impairment is not recommended. 
Uporaba pri bolnikih s hudo okvaro jeter ni priporočljiva.
As it is not known whether this medicone is excreted in human milk, do not use Moventig during breast-feeding. 
Ker ni znano, ali se to zdravilo izloča v materino mleko, zdravila Moventig ne uporabljajte med obdobjem dojenja.
The recommended dose is 1 tablet of 25 mg each day. 
Priporočeni odmerek je ena 25 mg tableta vsak dan.
SBM was defined as a bowel movement without rescue laxative taken within the past 24 hours. 
Spontano iztrebljanje je bilo opredeljeno kot iztrebljanje brez uporabe rešilnega odvajala v zadnjih 24 urah.
PEGylation reduces naloxegol's passive permeability and also renders the compound a substrate for the P-glycoprotein transporter. 
PEGilacija zmanjša pasivno permeabilnost naloksegola in hkrati doseže, da je spojina substrat za P-glikoproteinski prenašalec.
Embryo-foetal development studies were conducted in rats and rabbits. 
Študije embrio-fetalnega razvoja so izvedli na podganah in kuncih.
Take Moventig in the morning, to avoid bowel movements in the middle of the night. 
Zdravilo Moventig vzemite zjutraj, da se ne bo tiščanje na blato pojavilo sredi noči.
• vascular endothelial growth factor (VEGF) inhibitor treatment. 
• ki se zdravijo z zaviralcem žilnega endotelijskega rastnega dejavnika (vascular endothelial growth factor - VEGF).
• medicines called ‘opioid antagonists' (such as naltrexone and naloxone) which are used to counteract the effects of opioids 
• zdravila, ki se imenujejo ‘opioidni antagonisti' (na primer naltrekson in nalokson), ki se uporabljajo za nevtraliziranje učinkov opioidov.
Moventig should be taken on an empty stomach at least 30 minutes before the first meal of the day or 2 hours after the first meal. 
Moventig je treba vzeti na prazen želodec vsaj 30 minut pred prvim dnevnim obrokom ali 2 uri po njem.
For patients who are unable to swallow the tablet whole, the tablet can be crushed to a powder and mixed in half a glass of water (120 ml) and drunk immediately. 
Bolniki, ki tablete ne morejo pogoltniti cele, lahko tableto zdrobijo v prašek, ki ga zmešajo s pol kozarca vode (120 ml) in takoj popijejo.
Tell your doctor immediately, you may need a lower dose or to stop taking Moventig. 
O tem morate nemudoma obvestiti zdravnika: morda potrebujete manjši odmerek ali boste morali nehati jemati zdravilo Moventig.
In a majority of subjects, a secondary plasma concentration peak of naloxegol was observed approximately 0.4 to 3 hours after the first peak. 
Pri večini preiskovancev so drugi vrh koncentracije naloksegola v plazmi opažali približno 0,4 do 3 ure po prvem vrhu.
Response over 12 weeks in patients with an inadequate response to at least two classes of laxative Response to naloxegol over 12 weeks was tested in the sub-group of patients with inadequate response to at least two laxative classes, approximately 20% of the patients randomized. 
Odziv v 12 tednih pri bolnikih z nezadostnim odzivom na vsaj dve skupini odvajal Odziv na naloksegol v obdobju 12 tednov so testirali v podskupini bolnikov z nezadostnim odzivom na vsaj dve skupini odvajal, približno 20 % randomiziranih bolnikov.
• recurrent or advanced ovarian cancer 
• s ponovitvijo ali napredovanjem raka jajčnika,
For information regarding concomitant use with CYP3A4 inhibitors, see sections 4.2, 4.3 and 4.5. 
Za informacije o sočasni uporabi z zaviralci CYP3A4 glejte poglavja 4.2, 4.3 in 4.5.
Patients taking methadone for treatment of opioid addiction were not included in the clinical development programme and use of naloxegol in these patients should be approached with caution. 
Bolniki, ki jemljejo metadon za zdravljenje zasvojenosti z opioidi, niso bili vključeni v program kliničnega razvoja in pri takšnih bolnikih je treba naloksegol uporabljati previdno.
The starting dose for patients with moderate or severe renal insufficiency is 12.5 mg. 
Začetni odmerek za bolnike z zmerno ali hudo okvaro ledvic je 12,5 mg.
Do not use Moventig if any of the above applies to you. 
Ne uporabljajte zdravila Moventig, če kaj od naštetega velja za vas.
Tell your doctor, pharmacist or nurse if you are taking any of the following medicines: 
Zdravniku, farmacevtu ali medicinski sestri povejte, če jemljete katero od naslednjih zdravil:
• diltiazem or verapamil (for high blood pressure or angina). 
• diltiazem ali verapamil (za visok krvni tlak ali angino pektoris).
Use of naloxegol with another opioid antagonist (e.g. naltrexone, naloxone) should be avoided due to the potential for an additive effect of opioid receptor antagonism and an increased risk of opioid withdrawal. 
Interakcije z drugimi opioidnimi antagonisti Uporabi naloksegola s kakim drugim opioidnim antagonistom (npr. naltreksonom, naloksonom) se je treba izogibati zaradi možnosti aditivnega učinka antagonizma na opioidnem receptorju in zvečanega tveganja odtegnitve opioidov.
In a clinical study of patients with OIC, a daily dose of 50 mg was associated with an increased incidence of intolerable gastrointestinal effects (primarily abdominal pain). 
klinični študiji bolnikov z OIC je bil dnevni odmerek 50 mg povezan z večjo incidenco nevzdržnih učinkov na prebavilih (predvsem bolečin v trebuhu).
• if you are taking certain other medicines such as ketoconazole or itraconazole (to treat fungal infections), clarithromycin or telithromycin (antibiotics) or ritonavir, indinavir or saquinavir (to treat HIV). 
• če jemljete določena druga zdravila, na primer ketokonazol ali itrakonazol (za zdravljenje glivičnih okužb), klaritromicin ali telitromicin (antibiotika) ali ritonavir, indinavir ali sakvinavir (za zdravljenje HIV).
Naloxegol exposure was found to increase with increased weight, however, the differences in exposure were not considered clinically relevant. 
Ugotovili so, da se izpostavljenost naloksegolu povečuje s telesno maso, vendar razlik v izpostavljenosti niso ocenili kot klinično pomembnih.
The efficacy and safety of naloxegol was established in two replicate double-blind, placebo-controlled studies in patients with OIC and non-cancer related pain (Kodiac 4 and Kodiac 5). 
Učinkovitost in varnost naloksegola so ugotovili v dveh repliciranih dvojno slepih, s placebom kontroliranih študijah pri bolnikih z OIC in bolečinami, nepovezanimi z rakom (Kodiac 4 in
During the 52-week treatment period there were no important unexpected differences in the safety and tolerability findings between the naloxegol 25 mg treatment group and the usual care treatment group. 
Med 52-tedenskim obdobjem zdravljenja niso ugotovili pomembnih nepričakovanih razlik glede varnosti in prenašanja med skupino, ki je prejemala 25 mg naloksegola, in skupino, deležno običajnega zdravljenja.
Effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of naloxegol was not evaluated. 
Vpliva hude okvare jeter (Child-Pugh razred C) na farmakokinetiko naloksegola niso ocenili.
Studies in suckling rats have shown that naloxegol is excreted in the milk. 
Študije na dojenih podganah so pokazale, da se naloksegol izloča v mleko.
This is because large amounts can affect how much of the naloxegol medicine gets into the body. 
Velika količina grenivkinega soka namreč lahko vpliva na to, koliko naloksegola pride v telo.
• rifampin (an antibiotic), carbmazepine (for epilepsy) or the herbal medicine St. John's wort (for depression). 
• rifampin (antibiotik), karbamazepin (za epilepsijo) ali zeliščno zdravilo šentjanževko (za depresijo).